688321.SH
微芯生物
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 25.89
−7.37%Year over year
Reported trailing growth
- Revenue
- +45.7%
- EBITDA
- —
- EBIT
- +154.4%
- EPS
- +184.2%
- Free cash flow
- +10.6%
- Operating cash flow
- +67.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +19.8%
- EBITDA
- +28.7%
- EBIT
- +46.4%
- Net income
- +42.8%
- EPS
- +42.7%
- Free cash flow
- +57.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026